Skip to main content
رجوع
CAPR logo

Capricor Therapeutics, Inc.

جودة البيانات: 100%
CAPR
NASDAQ Healthcare Biotechnology
KWD 30.10
▲ KWD 1.00 (3.44%)
القيمة السوقية: 1.38B
نطاق اليوم
KWD 28.15 KWD 30.32
نطاق 52 أسبوعًا
KWD 4.30 KWD 40.37
حجم التداول
1,311,263
متوسط 50 يوم / 200 يوم
KWD 26.28 / KWD 14.68
الإغلاق السابق
KWD 29.10

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (626 نظير)

المقياس السهم وسيط القطاع
P/E -13.1 0.4
P/B 4.5 2.9
ROE % -46.6 3.7
Net Margin % 3.9
Rev Growth 5Y % 10.0
D/E 0.1 0.2

السعر المستهدف للمحللين

Hold
KWD 47.750 +58.6%
Low: KWD 13.000 High: KWD 62.000
مكرر الربحية المستقبلي
154.4
ربحية السهم المستقبلية
KWD 0.195
نمو ربحية السهم (تقدير)
+0.0%
الإيرادات المقدّرة
150 M

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 6.313
-KWD 1.430 – KWD 15.113
680 M 1
FY2029 KWD 4.032
-KWD 0.913 – KWD 9.653
450 M 1
FY2028 KWD 2.040
KWD 1.040 – KWD 4.940
280 M 5

النقاط الرئيسية

Debt/Equity of 0.07 — conservative balance sheet
Negative free cash flow of -72.72B

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)-100.00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-46.56%
ROIC-24.82%
Net MarginN/A
Op. MarginN/A

الأمان

Debt / Equity
0.07
Current Ratio9.01
Interest Coverage-35.51

التقييم

P/E Ratio
-13.10
P/B Ratio4.50
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -100.00% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0.0 Net Income (TTM) -105.04M
ROE -46.56% ROA -29.51%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -72.72B
ROIC -24.82% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.07 Current Ratio 9.01
Interest Coverage -35.51 Dividend Yield 0.00%
Valuation
P/E Ratio -13.10 P/B Ratio 4.50
P/S Ratio N/A PEG Ratio -0.13
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 1.38B Enterprise Value 1.11B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0.0 22.27M 25.18M 2.55M 244,898.0
Net Income -105.04M -40.47M -22.29M -29.02M -20.02M
EPS (Diluted) -2.26 -1.15 -0.83 -1.18 -0.87
Gross Profit 0.0 -27.70M -11.27M -19.27M 244,898.0
Operating Income -108.14M -42.56M -24.08M -29.70M -20.94M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 355.95M 170.48M 58.73M 50.09M 41.33M
Total Liabilities 50.16M 25.02M 36.13M 38.31M 9.96M
Shareholders' Equity 305.79M 145.46M 22.60M 11.79M 31.37M
Total Debt 20.94M 1.45M 2.24M 2.56M 2.87M
Cash & Equivalents 287.85M 11.29M 14.69M 9.60M 34.89M
Current Assets 322.94M 163.39M 50.86M 42.89M 36.44M
Current Liabilities 35.84M 21.03M 31.27M 23.59M 4.13M